Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for RCKT

Stock Name	Rocket Pharmaceuticals Inc
Ticker	RCKT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US77313F1066
LEI	549300R7VV82YUIN4Y93

Show aggregate RCKT holdings

News associated with RCKT

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $16.73 Consensus Price Target from Brokerages: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been given an average recommendation of “Hold” by the seventeen research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have issued a buy recommendation on […] - 2025-09-08 03:08:52
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Upgraded by Bank of America: Bank of America upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) from a neutral rating to a buy rating in a research note issued to investors on Wednesday, Marketbeat.com reports. They currently have $10.00 price objective on the biotechnology company’s stock, up from their prior price objective of $4.00. Several other equities analysts also […] - 2025-08-21 04:58:50
Pre-Market Most Active for Aug 20, 2025 : OPEN, RCKT, TSLL, SQQQ, PLTR, NVDA, TGT, NIO, BBAI, ZIM, JHX, ACHR: The NASDAQ 100 Pre-Market Indicator is down -41.62 to 23,343.15. The total Pre-Market volume is currently 119,921,297 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is -0.18 at $3.44, with 13,354,852 shares tra - 2025-08-20 09:29:56
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Hold” from Brokerages: Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given an average recommendation of “Hold” by the seventeen analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating […] - 2025-08-11 02:48:58
Canaccord Genuity Group Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $10.00: Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price trimmed by Canaccord Genuity Group from $11.00 to $10.00 in a research report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. UBS Group reduced their target […] - 2025-07-28 04:40:54
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $18.60 Consensus Target Price from Analysts: Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given a consensus recommendation of “Hold” by the seventeen analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the […] - 2025-06-25 03:02:58
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by The Goldman Sachs Group: Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports. A number of other research firms have also recently weighed in on RCKT. JPMorgan Chase & Co. cut […] - 2025-05-30 04:34:55
Chardan Capital Lowers Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $17.00: Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target reduced by research analysts at Chardan Capital from $46.00 to $17.00 in a report released on Wednesday, MarketBeat.com reports. The firm presently has a “buy” rating on the biotechnology company’s stock. RCKT has been the topic of several other research reports. Jefferies Financial Group […] - 2025-05-30 04:34:54
Morgan Stanley Reiterates Equal Weight Rating for Rocket Pharmaceuticals (NASDAQ:RCKT): Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “equal weight” rating restated by equities researchers at Morgan Stanley in a note issued to investors on Wednesday, MarketBeat Ratings reports. They currently have a $7.00 target price on the biotechnology company’s stock. Morgan Stanley’s target price suggests a potential upside of 167.18% from the […] - 2025-05-30 04:34:51
Jefferies Financial Group Reiterates “Hold” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT): Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. cut their target price […] - 2025-05-30 02:16:46
Rocket Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RCKT): Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) saw unusually large options trading on Tuesday. Traders acquired 2,414 call options on the company. This is an increase of 426% compared to the typical volume of 459 call options. Rocket Pharmaceuticals Stock Performance RCKT opened at $2.48 on Thursday. The stock’s 50 day simple moving average […] - 2025-05-29 05:14:57
BMO Capital Markets Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price: Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price target trimmed by BMO Capital Markets from $30.00 to $8.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the stock. Cantor Fitzgerald upped their […] - 2025-05-29 04:40:53
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 3,985 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 2.3% in the 4th quarter, HoldingsChannel reports. The fund owned 177,548 shares of the biotechnology company’s stock after buying an additional 3,985 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Rocket Pharmaceuticals were […] - 2025-05-22 05:51:02
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $30.00: Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price target increased by Cantor Fitzgerald from $20.00 to $30.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Rocket Pharmaceuticals’ FY2025 earnings at ($2.28) EPS. RCKT has […] - 2025-05-19 03:12:47
Voya Investment Management LLC Sells 1,493 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Voya Investment Management LLC trimmed its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,975 shares of the biotechnology company’s stock after selling 1,493 shares […] - 2025-05-13 05:20:49
Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price: Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its target price cut by Canaccord Genuity Group from $36.00 to $34.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on the stock. Scotiabank raised their […] - 2025-05-13 02:56:45
Raymond James Financial Inc. Makes New $285,000 Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Raymond James Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 22,645 shares of the biotechnology company’s stock, valued at approximately $285,000. Several other large investors have also recently bought and sold shares of the company. SG Americas Securities […] - 2025-05-12 04:20:58
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $45.00 at Chardan Capital: Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective decreased by Chardan Capital from $54.00 to $45.00 in a research note issued to investors on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock. Several other equities analysts also recently commented on the company. BMO Capital Markets assumed coverage […] - 2025-05-12 02:38:47
Mariner LLC Takes Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Mariner LLC bought a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,061 shares of the biotechnology company’s stock, valued at approximately $139,000. Other institutional investors […] - 2025-05-09 04:36:56
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) PT at $43.00: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 […] - 2025-05-06 03:07:08
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by Legal & General Group Plc: Legal & General Group Plc raised its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 3.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 75,454 shares of the biotechnology company’s stock after purchasing an additional 2,416 shares during the quarter. […] - 2025-04-28 04:56:54
Raymond James Financial Inc. Acquires Shares of 22,645 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Raymond James Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 22,645 shares of the biotechnology company’s stock, valued at approximately $285,000. Other hedge funds and other institutional investors have also made changes to their positions in the […] - 2025-04-11 04:56:49
Mitsubishi UFJ Asset Management Co. Ltd. Has $254,000 Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 68.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,196 shares of the biotechnology company’s stock after buying an additional 8,190 […] - 2025-04-04 05:12:55
Blair William & Co. IL Reduces Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Blair William & Co. IL reduced its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 14.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 116,038 shares of the biotechnology company’s stock after selling 18,931 shares during the quarter. Blair William & Co. IL’s holdings in Rocket Pharmaceuticals were worth […] - 2025-04-03 05:27:07
Teacher Retirement System of Texas Purchases 7,211 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Teacher Retirement System of Texas raised its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 45.2% during the 4th quarter, Holdings Channel reports. The fund owned 23,148 shares of the biotechnology company’s stock after purchasing an additional 7,211 shares during the period. Teacher Retirement System of Texas’ holdings in Rocket Pharmaceuticals […] - 2025-04-02 04:42:48
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by Signaturefd LLC: Signaturefd LLC grew its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 319.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,916 shares of the biotechnology company’s stock after buying an additional 3,745 shares during the quarter. Signaturefd LLC’s holdings […] - 2025-03-25 06:03:00
Harbour Investments Inc. Acquires 1,840 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT): Harbour Investments Inc. lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 51.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,385 shares of the biotechnology company’s stock after acquiring an additional 1,840 shares during the period. Harbour Investments Inc.’s holdings in Rocket Pharmaceuticals were worth $68,000 as of […] - 2025-03-24 06:02:55
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Moderate Buy” from Analysts: Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The […] - 2025-03-14 05:12:56
Canaccord Genuity Group Has Lowered Expectations for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price: Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target lowered by research analysts at Canaccord Genuity Group from $39.00 to $36.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 315.70% […] - 2025-03-05 08:08:58
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) shares reached a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $29.00 to $15.00. The Goldman Sachs Group currently has a neutral rating on the stock. Rocket Pharmaceuticals traded as low as $8.93 and last traded at […] - 2025-03-04 04:56:43

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) RCKT holdings

Date	Number of RCKT Shares Held	Base Market Value of RCKT Shares	Local Market Value of RCKT Shares	Change in RCKT Shares Held	Change in RCKT Base Value	Current Price per RCKT Share Held	Previous Price per RCKT Share Held
2025-12-03 (Wednesday)	74,518	USD 248,890	USD 248,890	0	USD 18,629	USD 3.34	USD 3.09001
2025-12-02 (Tuesday)	74,518	USD 230,261	USD 230,261	2,760	USD 3,506	USD 3.09001	USD 3.16
2025-12-01 (Monday)	71,758	USD 226,755	USD 226,755	0	USD -18,657	USD 3.16	USD 3.42
2025-11-28 (Friday)	71,758	USD 245,412	USD 245,412	184	USD 9,934	USD 3.42	USD 3.28999
2025-11-27 (Thursday)	71,574	USD 235,478	USD 235,478	0	USD 0	USD 3.28999	USD 3.28999
2025-11-26 (Wednesday)	71,574	USD 235,478	USD 235,478	552	USD 15,310	USD 3.28999	USD 3.1
2025-11-25 (Tuesday)	71,022	USD 220,168	USD 220,168	920	USD 7,759	USD 3.1	USD 3.03
2025-11-24 (Monday)	70,102	USD 212,409	USD 212,409	184	USD 7,549	USD 3.03	USD 2.93
2025-11-21 (Friday)	69,918	USD 204,860	USD 204,860	0	USD 6,293	USD 2.93	USD 2.84
2025-11-20 (Thursday)	69,918	USD 198,567	USD 198,567	-732	USD -4,905	USD 2.84	USD 2.88
2025-11-19 (Wednesday)	70,650	USD 203,472	USD 203,472	182	USD -3,704	USD 2.88	USD 2.94
2025-11-18 (Tuesday)	70,468	USD 207,176	USD 207,176	1,092	USD -3,727	USD 2.94	USD 3.04
2025-11-17 (Monday)	69,376	USD 210,903	USD 210,903	364	USD 416	USD 3.04	USD 3.05001

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RCKT by Blackrock for IE00BDZVHG35

Show aggregate share trades of RCKT

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 2,760 3.210 3.080 3.093 USD 8,537 7.41
2025-11-28 BUY 184 3.420* 7.45
2025-11-26 BUY 552 3.300 3.050 3.075 USD 1,697 7.49
2025-11-26 BUY 552 3.300 3.050 3.075 USD 1,697 7.49
2025-11-25 BUY 920 3.120 2.980 2.994 USD 2,754 7.52
2025-11-24 BUY 184 3.045 2.910 2.924 USD 538 7.54
2025-11-20 SELL -732 2.840* 7.59 Profit of 5,553 on sale
2025-11-19 BUY 182 2.880* 7.61
2025-11-18 BUY 1,092 2.940* 7.64
2025-11-17 BUY 364 3.110 2.975 2.988 USD 1,088 7.66
2025-11-14 BUY 182 3.249 3.020 3.043 USD 554 7.68
2025-11-12 BUY 182 3.300* 7.73
2025-11-10 BUY 181 3.230 3.120 3.131 USD 567 7.78
2025-11-06 BUY 180 3.350 3.160 3.179 USD 572 7.83
2025-11-04 BUY 181 3.530 3.285 3.310 USD 599 7.88
2025-10-30 BUY 905 3.840 3.690 3.705 USD 3,353 7.95
2025-10-29 BUY 362 3.780 3.945 3.928 USD 1,422 7.97
2025-10-22 SELL -716 3.800 3.970 3.953 USD -2,830 8.09 Profit of 2,963 on sale
2025-10-20 BUY 358 4.000 4.065 4.059 USD 1,453 8.14
2025-10-17 BUY 893 3.710 3.939 3.916 USD 3,497 8.17
2025-10-15 BUY 1,416 4.240 4.509 4.482 USD 6,347 8.19
2025-10-03 BUY 1,281 3.150 3.270 3.258 USD 4,173 8.24
2025-10-02 BUY 183 3.210 3.280 3.273 USD 599 8.27
2025-09-30 BUY 364 3.260 3.290 3.287 USD 1,196 8.33
2025-09-26 BUY 364 3.260 3.260 3.260 USD 1,187 8.40
2025-09-25 BUY 364 3.190 3.280 3.271 USD 1,191 8.43
2025-09-18 BUY 183 3.170 3.170 3.170 USD 580 8.46
2025-09-17 BUY 549 3.030 3.255 3.233 USD 1,775 8.50
2025-07-17 SELL -360 3.340 3.520 3.502 USD -1,261 8.63 Profit of 1,847 on sale
2025-07-11 SELL -1,456 2.960 3.140 3.122 USD -4,546 8.78 Profit of 8,245 on sale
2025-07-02 BUY 10,010 2.880 2.940 2.934 USD 29,369 8.94
2025-06-25 BUY 362 2.650 2.795 2.781 USD 1,007 9.12
2025-06-11 BUY 364 3.030 3.330 3.300 USD 1,201 9.59
2025-06-10 BUY 364 3.160 3.230 3.223 USD 1,173 9.64
2025-06-04 SELL -182 2.920 3.120 3.100 USD -564 9.85 Profit of 1,229 on sale
2025-04-23 BUY 177 7.140 7.440 7.410 USD 1,312 11.01
2025-04-10 SELL -1,424 4.940 5.400 5.354 USD -7,624 11.49 Profit of 8,745 on sale
2025-04-08 SELL -178 4.790 5.480 5.411 USD -963 11.64 Profit of 1,109 on sale
2025-04-07 SELL -178 5.190 5.300 5.289 USD -941 11.72 Profit of 1,144 on sale
2025-04-04 SELL -890 5.120 5.435 5.403 USD -4,809 11.79 Profit of 5,688 on sale
2025-04-01 BUY 728 5.810 6.650 6.566 USD 4,780 11.93
2025-03-31 SELL -534 6.670 7.275 7.215 USD -3,853 12.00 Profit of 2,554 on sale
2025-03-21 BUY 9,577 8.430 8.700 8.673 USD 83,061 12.31
2025-03-14 SELL -2,352 8.760 8.810 8.805 USD -20,709 12.57 Profit of 8,858 on sale
2025-03-07 SELL -292 8.770 9.110 9.076 USD -2,650 12.87 Profit of 1,109 on sale
2025-03-04 SELL -147 8.660 8.825 8.808 USD -1,295 13.06 Profit of 625 on sale
2025-02-25 BUY 292 9.360 10.170 10.089 USD 2,946 13.38
2025-02-19 SELL -145 10.920 11.080 11.064 USD -1,604 13.59 Profit of 367 on sale
2025-02-13 BUY 435 10.120 10.150 10.147 USD 4,414 13.84
2025-02-12 BUY 145 9.860 9.870 9.869 USD 1,431 13.92
2025-02-11 BUY 580 9.880 10.150 10.123 USD 5,871 14.01
2024-12-30 SELL -4,829 12.030 12.270 12.246 USD -59,136 15.42 Profit of 15,310 on sale
2024-11-18 SELL -2,355 13.660 14.250 14.191 USD -33,420 17.18 Profit of 7,046 on sale
2024-11-08 SELL -157 17.450 17.660 17.639 USD -2,769 17.25 Loss of -62 on sale
2024-10-21 SELL -157 17.620 18.870 18.745 USD -2,943 0.00 Loss of -2,943 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	2,760	3.210	3.080	3.093	USD 8,537	7.41
2025-11-28	BUY	184			3.420*		7.45
2025-11-26	BUY	552	3.300	3.050	3.075	USD 1,697	7.49
2025-11-26	BUY	552	3.300	3.050	3.075	USD 1,697	7.49
2025-11-25	BUY	920	3.120	2.980	2.994	USD 2,754	7.52
2025-11-24	BUY	184	3.045	2.910	2.924	USD 538	7.54
2025-11-20	SELL	-732			2.840*		7.59 Profit of 5,553 on sale
2025-11-19	BUY	182			2.880*		7.61
2025-11-18	BUY	1,092			2.940*		7.64
2025-11-17	BUY	364	3.110	2.975	2.988	USD 1,088	7.66
2025-11-14	BUY	182	3.249	3.020	3.043	USD 554	7.68
2025-11-12	BUY	182			3.300*		7.73
2025-11-10	BUY	181	3.230	3.120	3.131	USD 567	7.78
2025-11-06	BUY	180	3.350	3.160	3.179	USD 572	7.83
2025-11-04	BUY	181	3.530	3.285	3.310	USD 599	7.88
2025-10-30	BUY	905	3.840	3.690	3.705	USD 3,353	7.95
2025-10-29	BUY	362	3.780	3.945	3.928	USD 1,422	7.97
2025-10-22	SELL	-716	3.800	3.970	3.953	USD -2,830	8.09 Profit of 2,963 on sale
2025-10-20	BUY	358	4.000	4.065	4.059	USD 1,453	8.14
2025-10-17	BUY	893	3.710	3.939	3.916	USD 3,497	8.17
2025-10-15	BUY	1,416	4.240	4.509	4.482	USD 6,347	8.19
2025-10-03	BUY	1,281	3.150	3.270	3.258	USD 4,173	8.24
2025-10-02	BUY	183	3.210	3.280	3.273	USD 599	8.27
2025-09-30	BUY	364	3.260	3.290	3.287	USD 1,196	8.33
2025-09-26	BUY	364	3.260	3.260	3.260	USD 1,187	8.40
2025-09-25	BUY	364	3.190	3.280	3.271	USD 1,191	8.43
2025-09-18	BUY	183	3.170	3.170	3.170	USD 580	8.46
2025-09-17	BUY	549	3.030	3.255	3.233	USD 1,775	8.50
2025-07-17	SELL	-360	3.340	3.520	3.502	USD -1,261	8.63 Profit of 1,847 on sale
2025-07-11	SELL	-1,456	2.960	3.140	3.122	USD -4,546	8.78 Profit of 8,245 on sale
2025-07-02	BUY	10,010	2.880	2.940	2.934	USD 29,369	8.94
2025-06-25	BUY	362	2.650	2.795	2.781	USD 1,007	9.12
2025-06-11	BUY	364	3.030	3.330	3.300	USD 1,201	9.59
2025-06-10	BUY	364	3.160	3.230	3.223	USD 1,173	9.64
2025-06-04	SELL	-182	2.920	3.120	3.100	USD -564	9.85 Profit of 1,229 on sale
2025-04-23	BUY	177	7.140	7.440	7.410	USD 1,312	11.01
2025-04-10	SELL	-1,424	4.940	5.400	5.354	USD -7,624	11.49 Profit of 8,745 on sale
2025-04-08	SELL	-178	4.790	5.480	5.411	USD -963	11.64 Profit of 1,109 on sale
2025-04-07	SELL	-178	5.190	5.300	5.289	USD -941	11.72 Profit of 1,144 on sale
2025-04-04	SELL	-890	5.120	5.435	5.403	USD -4,809	11.79 Profit of 5,688 on sale
2025-04-01	BUY	728	5.810	6.650	6.566	USD 4,780	11.93
2025-03-31	SELL	-534	6.670	7.275	7.215	USD -3,853	12.00 Profit of 2,554 on sale
2025-03-21	BUY	9,577	8.430	8.700	8.673	USD 83,061	12.31
2025-03-14	SELL	-2,352	8.760	8.810	8.805	USD -20,709	12.57 Profit of 8,858 on sale
2025-03-07	SELL	-292	8.770	9.110	9.076	USD -2,650	12.87 Profit of 1,109 on sale
2025-03-04	SELL	-147	8.660	8.825	8.808	USD -1,295	13.06 Profit of 625 on sale
2025-02-25	BUY	292	9.360	10.170	10.089	USD 2,946	13.38
2025-02-19	SELL	-145	10.920	11.080	11.064	USD -1,604	13.59 Profit of 367 on sale
2025-02-13	BUY	435	10.120	10.150	10.147	USD 4,414	13.84
2025-02-12	BUY	145	9.860	9.870	9.869	USD 1,431	13.92
2025-02-11	BUY	580	9.880	10.150	10.123	USD 5,871	14.01
2024-12-30	SELL	-4,829	12.030	12.270	12.246	USD -59,136	15.42 Profit of 15,310 on sale
2024-11-18	SELL	-2,355	13.660	14.250	14.191	USD -33,420	17.18 Profit of 7,046 on sale
2024-11-08	SELL	-157	17.450	17.660	17.639	USD -2,769	17.25 Loss of -62 on sale
2024-10-21	SELL	-157	17.620	18.870	18.745	USD -2,943	0.00 Loss of -2,943 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RCKT

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	563,064	2,715	1,108,580	50.8%
2025-09-18	353,571	10	944,624	37.4%
2025-09-17	645,882	2,296	1,194,287	54.1%
2025-09-16	195,624	0	653,209	29.9%
2025-09-15	462,762	1,028	1,038,978	44.5%
2025-09-12	444,850	0	857,654	51.9%
2025-09-11	334,960	3,831	760,216	44.1%
2025-09-10	232,361	0	582,569	39.9%
2025-09-09	386,675	0	927,059	41.7%
2025-09-08	192,047	0	513,692	37.4%
2025-09-05	164,317	0	692,426	23.7%
2025-09-04	350,317	0	986,373	35.5%
2025-09-03	468,331	650	1,309,072	35.8%
2025-09-02	234,988	0	793,310	29.6%
2025-08-29	610,073	2,000	1,209,947	50.4%
2025-08-28	629,779	0	2,341,107	26.9%
2025-08-27	395,886	3,030	1,379,014	28.7%
2025-08-26	371,104	0	1,528,873	24.3%
2025-08-25	480,953	0	1,422,025	33.8%
2025-08-22	1,263,187	2,566	3,984,213	31.7%
2025-08-21	2,224,158	27,883	4,641,016	47.9%
2025-08-20	18,811,477	68,385	29,439,628	63.9%
2025-08-19	621,567	152	1,001,122	62.1%
2025-08-18	338,544	101	679,552	49.8%
2025-08-15	269,076	166	608,744	44.2%
2025-08-14	326,439	180	581,152	56.2%
2025-08-13	527,424	0	1,350,764	39.0%
2025-08-12	439,983	0	946,921	46.5%
2025-08-11	544,633	3,000	1,045,698	52.1%
2025-08-08	824,583	150	1,428,673	57.7%
2025-08-07	401,658	0	805,250	49.9%
2025-08-06	406,534	1,143	942,469	43.1%
2025-08-05	417,260	0	901,997	46.3%
2025-08-04	275,187	6,300	534,220	51.5%
2025-08-01	329,543	200	720,277	45.8%
2025-07-31	300,551	0	628,549	47.8%
2025-07-30	768,471	0	1,834,722	41.9%
2025-07-29	352,714	923	765,856	46.1%
2025-07-28	340,513	0	1,133,963	30.0%
2025-07-25	359,766	0	1,066,131	33.7%
2025-07-24	462,482	21,000	1,595,337	29.0%
2025-07-23	441,203	0	1,579,840	27.9%
2025-07-22	425,715	450	1,791,951	23.8%
2025-07-21	476,263	9,877	1,518,341	31.4%
2025-07-18	546,823	424	1,687,391	32.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE